EarliPoint Health

EarliPoint Health is a mission-driven company focused on transforming autism care through objective, science-based diagnostic tools. Founded on decades of pioneering research from Yale and Emory universities, the company's FDA-cleared EarliPoint System measures social visual engagement to provide clinicians with actionable insights for earlier diagnosis and treatment monitoring. The company is commercializing its technology to healthcare providers, aiming to reduce diagnostic bottlenecks and improve lifelong outcomes for children with autism.

The EarliPoint System is a diagnostic platform that uses portable eye-tracking technology and proprietary algorithms to measure a child's patterns of visual attention to social scenes, providing objective biomarkers to aid in the assessment of Autism Spectrum Disorder.

Total raised: $36M

EarliPoint's primary competition is the established, subjective gold-standard diagnostic tools (ADOS, ADI-R) and the systemic bottleneck they create. Its main differentiation is providing objective, quantifiable, and faster biomarker data to aid the clinician. It faces limited direct competition from other FDA-cleared, objective diagnostic aids for autism, positioning it uniquely in the market.